Alliance model provides rapid global expansion, says inVentiv

By Gareth Macdonald

- Last updated on GMT

Related tags: Contract research organization

inVentiv Clinical Solutions' new Clinical Global Alliance will help meet industry demand for rapid access to “concentrated patient populations” according to CEO Michael Hlinak.

The network, launched yesterday with the announcement of a first partnership with Argentina based ActivaCro, is part of an effort to expand inVentiv’s global reach and boost efficiency through collaboration.

Hlinak told Outsourcing-Pharma that the idea “is to provide an integrated, responsive global network offering clinical research services outside the US.

Members will have passed quality assessments and will usually provide equity or other provisions in the alliance agreement to ensure inVentiv Clinical Solutions of a long term, meaningful collaboration.​”

Hlinak said that ActivaCro, a contract research organisation (CRO) that has operations in Buenos Aires as well as Chile, Uruguay and Mexico, “boasts an impressive track record of quality clinical trial execution.”

In a press statement, ActivaCro director Mario Boskis praised inVentiv as a leader in clinical outsourcing and added that his firm’s business will benefit from the US company’s existing client base.

Rapid access

Improving patient access by expansion is common strategy in the CRO sector, with South America emerging as one of the hot destinations for growth along with Asia -Pacific and, more recently, Central and Eastern Europe.

And, although inVentiv already has its own regional offices in India, Brazil, Taiwan and Spain, its new partnership approach to expansion has a number of advantages over going it alone as Hlinak explained.

Taking an integrated alliance approach offers rapid access to these [emerging] markets and brings immediate credibility and a history of performance.

The alternative start-up approach would require excessive time and would require investments that would not be consistent with the competitive value-driven pricing​.”

He went on to say that the firm plans to form partnerships in both Eastern and Western Europe and, long-term, hopes to capitalize on its presence in India and Taiwan to developer a broader Asia-Pacific capability for trials.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Related suppliers

Follow us


View more